+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Neuropathic Pain"

Cymbalta (duloxetine) Drug Overview 2019 - Product Thumbnail Image

Cymbalta (duloxetine) Drug Overview 2019

  • Report
  • March 2019
  • 25 Pages
  • Global
Neuropathic Pain Market and Forecast Analysis to 2026 - Product Thumbnail Image

Neuropathic Pain Market and Forecast Analysis to 2026

  • Report
  • October 2018
  • 293 Pages
  • Global
From
Global Pregabalin Market 2022-2026 - Product Thumbnail Image

Global Pregabalin Market 2022-2026

  • Report
  • September 2022
  • 120 Pages
  • Global
From
Pain Management Devices Market - Forecasts from 2021 to 2026 - Product Thumbnail Image

Pain Management Devices Market - Forecasts from 2021 to 2026

  • Report
  • July 2021
  • 116 Pages
  • Global
From
From
From
From
From
Diabetic Neuropathic Pain Global Clinical Trials Review, H2, 2019 - Product Thumbnail Image

Diabetic Neuropathic Pain Global Clinical Trials Review, H2, 2019

  • Clinical Trials
  • December 2019
  • 193 Pages
  • Global
From
Neuropathic Pain (Neuralgia) Global Clinical Trials Review, H2, 2019 - Product Thumbnail Image

Neuropathic Pain (Neuralgia) Global Clinical Trials Review, H2, 2019

  • Clinical Trials
  • December 2019
  • 1881 Pages
  • Global
From
Medical Marijuana - Thematic Research - Product Thumbnail Image

Medical Marijuana - Thematic Research

  • Report
  • November 2019
  • 186 Pages
  • Global
From
From
Loading Indicator

Neuropathic pain is a type of chronic pain caused by damage to the nervous system. It is often described as a burning, tingling, or shooting sensation. Analgesics are medications used to reduce or eliminate pain. Neuropathic pain is often treated with a combination of analgesics, including non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and anticonvulsants. Other treatments may include physical therapy, nerve blocks, and electrical stimulation. The neuropathic pain market is a rapidly growing segment of the analgesics market. It is driven by the increasing prevalence of chronic pain conditions, such as diabetes, cancer, and multiple sclerosis. The market is expected to benefit from the development of novel treatments, such as gene therapy and stem cell therapy. Some companies in the neuropathic pain market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more